Observational studyJournal of the Pediatric Infectious Diseases Society2018
A Multicenter Consortium to Define the Epidemiology and Outcomes of Inpatient Respiratory Viral Infections in Pediatric Hematopoietic Stem Cell Transplant Recipients.
Observational study in Journal of the Pediatric Infectious Diseases Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 72 citations in OpenAlex.
- Immunogenicity and Reactogenicity of High- or Standard-Dose Influenza Vaccine in a Second Consecutive Influenza Season.The Journal of infectious diseases · 2025Trial
- The Durability of Antibody Responses of Two Doses of High-Dose Relative to Two Doses of Standard-Dose Inactivated Influenza Vaccine in Pediatric Hematopoietic Cell Transplant Recipients: A Multi-Center Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Trial
- Burden and Risk Factors for Severe Respiratory Syncytial Virus Infection among Pediatric Hematopoietic Cell Transplant Recipients.Journal of the Pediatric Infectious Diseases Society · 2026Article
- Hospital-mandated restrictions during the COVID-19 pandemic alter hospital-acquired viral respiratory infections during hematopoietic stem cell transplantation: a single center pediatric experience.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- The Impact of Pretransplant Respiratory Virus Detection on Posttransplant Outcomes in Children Undergoing Hematopoietic Cell Transplantation.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Identification of Lower Respiratory Tract Pathogens in Cancer Patients: Insights into Fatal Outcomes.Microorganisms · 2024Article
- Respiratory Syncytial Virus Infections in Recipients of Bone Marrow Transplants: A Systematic Review and Meta-Analysis.Infectious disease reports · 2024Review
- Impact of Respiratory Viral Infections in Transplant Recipients.Journal of the Pediatric Infectious Diseases Society · 2024Review
- Clinical Outcomes of Human Rhinovirus/Enterovirus Infection in Pediatric Hemopoietic Cell Transplant Patients.Journal of the Pediatric Infectious Diseases Society · 2024Article
- How I approach: the transplant recipient with fever and pulmonary infiltrates.Frontiers in pediatrics · 2024Article
- Early pulmonary complications related to cancer treatment in children.Pediatric radiology · 2022Review
- When Viruses Meet Fungi: Tackling the Enemies in Hematology.Journal of fungi (Basel, Switzerland) · 2022Review
- Occurrence of influenza and bacterial infections in cancer patients receiving radiotherapy in Ghana.PloS one · 2022Article
- Hospitalizations for vaccine-preventable infections among pediatric hematopoietic cell transplantation recipients in the first 5 years after transplantation.Bone marrow transplantation · 2021Article
- Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study.The Lancet. Oncology · 2021Article
- SARS-CoV-2 viral clearance during bone marrow aplasia after allogeneic hematopoietic stem cell transplantation-A case report.Pediatric transplantation · 2021Article
- Risk factors for seasonal human coronavirus lower respiratory tract infection after hematopoietic cell transplantation.Blood advances · 2021Article
- Emergent Pneumonia in Children.Frontiers in pediatrics · 2021Review
- COVID-19 in Patients with Cancer.Advances in experimental medicine and biology · 2021Article
- Viral Respiratory Infections in Hematological Patients.Infectious diseases and therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRespiratory virus infections (RVIs) pose a threat to children undergoing hematopoietic stem cell transplantation (HSCT). In this era of sensitive molecular diagnostics, the incidence and outcome of HSCT recipients who are hospitalized with RVI (H-RVI) are not well described.
methodsA retrospective observational cohort of pediatric HSCT recipients (between January 2010 and June 2013) was assembled from 9 US pediatric transplant centers. Their medical charts were reviewed for H-RVI events within 1 year after their transplant. An H-RVI diagnosis required respiratory signs or symptoms plus viral detection (human rhinovirus/enterovirus, human metapneumovirus, influenza, parainfluenza, coronaviruses, and/or respiratory syncytial virus). The incidence of H-RVI was calculated, and the association of baseline HSCT factors with subsequent pulmonary complications and death was assessed.
resultsAmong 1560 HSCT recipients, 259 (16.6%) acquired at least 1 H-RVI within 1 year after their transplant. The median age of the patients with an H-RVI was lower than that of patients without an H-RVI (4.8 vs 7.1 years; P < .001). Among the patients with a first H-RVI, 48% required some respiratory support, and 14% suffered significant pulmonary sequelae. The all-cause and attributable case-fatality rates within 3 months of H-RVI onset were 11% and 5.4%, respectively. Multivariate logistic regression revealed that H-RVI onset within 60 days of HSCT, steroid use in the 7 days before H-RVI onset, and the need for respiratory support at H-RVI onset were associated with subsequent morbidity or death.
conclusionResults of this multicenter cohort study suggest that H-RVIs are relatively common in pediatric HSCT recipients and contribute to significant morbidity and death. These data should help inform interventional studies specific to each viral pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.